Versantis Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 13

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $47.9M

  • Investors
  • 1

Versantis General Information

Description

Operator of a drug development company intended to develop disruptive therapies for rare liver and pediatric diseases. The company offers an innovative liposomal-based intra-peritoneal fluid that acts as a clearance enhancer for a large spectrum of toxic metabolites accumulated during decompensated liver cirrhosis and clears ammonia from the body, thereby enabling physicians to treat patients with acute liver diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Technoparkstrasse 1
  • 8005 Zurich
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • Technoparkstrasse 1
  • 8005 Zurich
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Versantis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Merger/Acquisition 29-Sep-2022 $47.9M Completed Generating Revenue
12. Grant 13-Apr-2022 Completed Clinical Trials - General
11. Later Stage VC (Series B) 18-Sep-2019 Completed Clinical Trials - General
10. Early Stage VC (Series A) 04-Apr-2017 Completed Clinical Trials - General
9. Accelerator/Incubator 19-May-2016 Completed Clinical Trials - General
8. Grant 01-Jul-2015 Completed Clinical Trials - General
7. Seed Round 01-Mar-2015 Completed Clinical Trials - General
6. Grant 13-Aug-2014 Completed Clinical Trials - General
5. Grant 01-Jul-2014 $55.8K $112K Completed Clinical Trials - General
4. Debt - General 01-Jun-2014 $112K $112K Completed Clinical Trials - General
To view Versantis’s complete valuation and funding history, request access »

Versantis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series A
Series A 51,475 $44.1 $44.1 1x $44.1 22.82%
To view Versantis’s complete cap table history, request access »

Versantis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a drug development company intended to develop disruptive therapies for rare liver and pediatric diseases. T
Drug Discovery
Zurich, Switzerland
13 As of 2022

New York, NY

Mont-Saint-Guibert, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Versantis Competitors (42)

One of Versantis’s 42 competitors is Attune Pharmaceuticals, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Attune Pharmaceuticals Venture Capital-Backed New York, NY
Cellaion Formerly VC-backed Mont-Saint-Guibert, Belgium
Ochre Bio Venture Capital-Backed Oxford, United Kingdom
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
ABIONYX Pharma Formerly VC-backed Balma, France
You’re viewing 5 of 42 competitors. Get the full list »

Versantis Patents

Versantis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250339393-A1 Use of transmembrane ph gradient liposomes for treating hyperammonemic crisis associated with inborn errors of metabolism Pending 16-Nov-2022
WO-2024105101-A1 Use of transmembrane ph gradient liposomes for treating hyperammonemic crisis associated with inborn errors of metabolism Inactive 16-Nov-2022
CA-3221837-A1 Unsaturated hydroxamic acid derivatives and their use for the treatment and prevention of an ammonia-associated disease or disorder Pending 29-Jun-2021
JP-2018519370-A Method for preparing transmembrane ph gradient vesicles Active 04-May-2015
JP-6715265-B2 Method for preparing transmembrane ph gradient vesicles Active 04-May-2015 A61K9/127
To view Versantis’s complete patent history, request access »

Versantis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Versantis Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Altus Capital Partners PE/Buyout Minority
Esperante Ventures Corporate Venture Capital Minority
Gebert Rüf Foundation Accelerator/Incubator
Innosuisse Government
Invivo Partners Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Versantis FAQs

  • Where is Versantis headquartered?

    Versantis is headquartered in Zurich, Switzerland.

  • What is the size of Versantis?

    Versantis has 13 total employees.

  • What industry is Versantis in?

    Versantis’s primary industry is Drug Discovery.

  • Is Versantis a private or public company?

    Versantis is a Private company.

  • What is the current valuation of Versantis?

    The current valuation of Versantis is .

  • What is Versantis’s current revenue?

    The current revenue for Versantis is .

  • How much funding has Versantis raised over time?

    Versantis has raised $20.9M.

  • Who are Versantis’s investors?

    Altus Capital Partners, Esperante Ventures, Gebert Rüf Foundation, Innosuisse, and Invivo Partners are 5 of 16 investors who have invested in Versantis.

  • Who are Versantis’s competitors?

    Attune Pharmaceuticals, Cellaion, Ochre Bio, Sarepta Therapeutics, and ABIONYX Pharma are some of the 42 competitors of Versantis.

  • When was Versantis acquired?

    Versantis was acquired on 29-Sep-2022.

  • Who acquired Versantis?

    Versantis was acquired by Genfit.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process